Cancer and Metastasis Reviews

, Volume 9, Issue 3, pp 253–266

Vascular and interstitial barriers to delivery of therapeutic agents in tumors

  • Rakesh K. Jain
Article

Abstract

The efficacy in cancer treatment of novel therapeutic agents such as monoclonal antibodies, cytokines and effector cells has been limited by their inability to reach their targetin vivo in adequate quantities. Molecular and cellular biology of neoplastic cells alone has failed to explain the nonuniform uptake of these agents. This is not surprising since a solid tumorin vivo is not just a collection of cancer cells. In fact, it consists of two extracellular compartments: vascular and interstitial. Since no blood-borne molecule or cell can reach cancer cells without passing through these compartments, the vascular and interstitial physiology of tumors has received considerable attention in recent years. Three physiological factors responsible for the poor localization of macromolecules in tumors have been identified: (i) heterogeneous blood supply, (ii) elevated interstitial pressure, and (iii) large transport distances in the interstitium. The first factor limits the delivery of blood-borne agents to well-perfused regions of a tumor; the second factor reduces extravasation of fluid and macromolecules in the high interstitial pressure regions and also leads to an experimentally verifiable, radially outward convection in the tumor periphery which opposes the inward diffusion; and the third factor increases the time required for slowly moving macromolecules to reach distal regions of a tumor. Binding of the molecule to an antigen further lowers the effective diffusion rate by reducing the amount of mobile molecule. Although the effector cells are capable of active migration, peculiarities of the tumor vasculature and interstitium may be also responsible for poor delivery of lymphokine activated killer cells and tumor infiltrating lymphocytes in solid tumors. Due to micro- and macroscopic heterogeneities in tumors, the relative magnitude of each of these physiological barriers would vary from one location to another and from one day to the next in the same tumor, and from one tumor to another. If the genetically engineered macromolecules and effector cells, as well as low molecular weight cytotoxic agents, are to fulfill their clinical promise, strategies must be developed to overcome or exploit these barriers. Some of these strategies are discussed, and situations wherein these barriers may not be a problem are outlined. Finally, some therapies where the tumor vasculature or the interstitium may be a target are pointed out.

Key words

vascular permeability interstitial pressure microvascular pressure monoclonal antibodies LAK cells TILs biological response modifiers anti-angiogenic therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jain RK: Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 81: 570–576, 1989Google Scholar
  2. 2.
    Gullino PM: The internal milieu of tumors. Progr Exp Tumor Res 8: 1–25, 1966Google Scholar
  3. 3.
    Jain RK, Weissbrod J, Wei J: Mass transfer in tumors: Characterization and applications in chemotherapy. Adv Cancer Res 33: 251–310, 1980Google Scholar
  4. 4.
    Gerlowski LE, Jain RK: Physiologically-based pharmacokinetics: Principles and applications. J Pharm Sci 72: 1103–1127, 1983Google Scholar
  5. 5.
    Gullino PM: Extracellular compartments of solid tumors.In: Cancer Becker FF (ed), pp 327–354. Plenum Publishing Corporation, New York 1975Google Scholar
  6. 6.
    Folkman J: Tumor angiogenesis. Adv Cancer Res 43: 175–203, 1985Google Scholar
  7. 7.
    Jain RK: Determinants of tumor blood flow: A review. Cancer Res 48: 2641–2658, 1988Google Scholar
  8. 8.
    Less J, Skalak T, Sevick EM, Jain RK: Microvascular architecture in a mammary carcinoma: Branching patterns and vessel dimensions. (Submitted)Google Scholar
  9. 9.
    Algire GH, Chalkley HW: Vascular reactions of normal and malignant tissuesin vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6: 73–85, 1945Google Scholar
  10. 10.
    Gullino PM, Grantham FH: The vascular space of growing tumors. Cancer Res 24: 1727–1732, 1964Google Scholar
  11. 11.
    Jain RK, Ward-Hartley K: Tumor blood flow-characterization, modification, and role in hyperthermia. IEEE Transactions on Sonics and Ultrasonics SU-31: 504–526, 1984Google Scholar
  12. 12.
    Vaupel P, Kallinowski F, Okunielf P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 49: 6449–6459, 1989Google Scholar
  13. 13.
    Ide AG, Baker NH, Warren SL: Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol 41 891–899, 1939Google Scholar
  14. 14.
    Endrich B, Reinhold HA, Gross JF, Intaglietta M: Tissue perfusion inhomogeneity during early tumor growth in rats. J Natl Cancer Inst 62: 387–395, 1979Google Scholar
  15. 15.
    Dudar TE, Jain RK: Differential responses of normal and tumor microcirculation to hyperthermia. Cancer Res 44: 605–612, 1984Google Scholar
  16. 16.
    Sevick EM, Jain RK: Geometric resistance to blood flow in solid tumors perfusedex vivo: Effects of tumor size and perfusion pressure. Cancer Res 49: 3506–3512, 1989Google Scholar
  17. 17.
    Sevick EM, Jain RK: Viscous resistance to blood flow in solid tumors: Effect of hematocrit on intratumor blood viscosity. Cancer Res 49: 3513–3519, 1989Google Scholar
  18. 18.
    Straw J, Hart M, Klubes P, Zahrako D, Dedrick RL: Distribution of anticancer agents in spontaneous animal tumors. I. Regional blood flow and methotrexate distribution in canine lymphosarcoma. J Natl Cancer Inst 52: 1327–1331, 1974Google Scholar
  19. 19.
    Beaney RP, Lammertsma AA, Jones T, McKenzie CG, Halnan KE:In vivo measurements of regional blood flow, oxygen utilization and blood volume in patients with carcinoma of the breast using positron tomography. Lancet 1: 131–133, 1984Google Scholar
  20. 20.
    Jain RK: Transport of molecules across tumor vasculature. Cancer and Metastasis Reviews 6: 559–594, 1987Google Scholar
  21. 21.
    Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Amer J Pathol 133: 95–109, 1988Google Scholar
  22. 22.
    Sevick E, Jain RK: Measurement of capillary filtration coefficients in a solid tumor. Microvascular Res, in pressGoogle Scholar
  23. 23.
    Gerlowski LE, Jain RK: Effect of hyperthermia on microvascular permeability of normal and neoplastic tissues. Intl J Microcirc: Clinical Exptl 4: 336–372, 1985Google Scholar
  24. 24.
    Jain RK: Transport of macromolecules in tumor microcirculation. Biotech Progress, 1: 81–94, 1985Google Scholar
  25. 25.
    Jain RK, Baxter LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 48: 7022–7032, 1988Google Scholar
  26. 26.
    Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convention. Microvasc Res 37: 77–104, 1989Google Scholar
  27. 27.
    Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res, in pressGoogle Scholar
  28. 28.
    Young JS, Lumsden CE, Stalker AL: The significance of the ‘tissue pressure’ of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol 62: 313–333, 1950Google Scholar
  29. 29.
    Jain RK: Transport of molecules in the tumor interstitium: A review. Cancer Res 47: 3039–3051, 1987Google Scholar
  30. 30.
    Boucher Y, Baxter LT, Jain RK: Interstitial fluid pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Res 50: 4478–4487, 1990Google Scholar
  31. 31.
    Wiig H, Tveit E, Hultborn R, Reed RK, Weiss L: Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand J Clin Lab Invest 42: 159–164, 1982Google Scholar
  32. 32.
    Misiewicz M: Microvascular and interstitial pressures in normal and neoplastic tissues. Thesis MS, Carnegie Mellon University, 1986Google Scholar
  33. 33.
    Sylven B, Bois I: I Protein content and enzymatic assays of interstitial fluid from some normal tissues and transplanted mouse tumors. Cancer Res 20: 831–835, 1960Google Scholar
  34. 34.
    Chary SR, Jain RK: Direct measurement of interstitial diffusion and convection of albumin in normal and neoplastic tissues using fluorescence photobleaching. Proc Natl Acad Sci (USA) 86: 5385–5389, 1989Google Scholar
  35. 35.
    Swabb EA, Wei J, Gullino PM: Diffusion and convection in normal and neoplastic tissues. Cancer Res 34: 2814–2822, 1974Google Scholar
  36. 36.
    Nugent LJ, Jain RK: Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44: 238–244, 1984Google Scholar
  37. 37.
    Gerlowski LE, Jain RK: Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31: 288–305, 1986Google Scholar
  38. 38.
    Clauss MA, Jain RK: Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res 50: 3487–3492, 1990Google Scholar
  39. 39.
    Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach JP: Penetration and binding of radiolabelled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res 47: 1627–1633, 1987Google Scholar
  40. 40.
    Astarita G: Mass Transfer with Chemical Reactions. Elsevier, Amsterdam, 1967Google Scholar
  41. 41.
    Fujimoni K, Covell DG, Fletcher JE, Weinstein JN: Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res 49: 5656–5663, 1989Google Scholar
  42. 42.
    Dedrick RL, Flessner MF: Pharmacokinetic Considerations of Monoclonal Antibodies.In: Mitchell M (ed): Immunity to Cancer II, pp 429–438, Liss AR, New York, 1989Google Scholar
  43. 43.
    Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. (Submitted)Google Scholar
  44. 44.
    Kaufman E, Jain RK: Simultaneous determination of transport and binding parameters using photobleaching: Potential for microcirculatory applications. Biophys J, in pressGoogle Scholar
  45. 45.
    Butler TP, Grantham FH, Gullino PM: Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res 35: 3084–3088, 1975Google Scholar
  46. 46.
    Vaupel P, Kallinowski F: Hemoconcentration of blood flowing through human tumor xenografts (Abstract). Intl J Microcirc: Clin Exptl 6: 72, 1987Google Scholar
  47. 47.
    Sevick EM, Jain RK: Blood flow and venous pH of tissueisolated Walker 256 carcinoma during hyperglycemia. Cancer Res 48: 1201–1207, 1988Google Scholar
  48. 48.
    Jain RK: Tumor Blood Flow Response to Heat and Pharmacological Agents.In: Fielden EM, Fowler JF, Hendry JH, Scott D (eds) Radiation Research (Proc 8th ICRR) Vol 2, pp 813–818. London: Taylor and Francis, 1987Google Scholar
  49. 49.
    Stickney DR, Grindley DS, Kirk GA, Slater JM: Enhancement of monoclonal antibody binding to melanoma with a single dose radiation or hyperthermia. Natl Cancer Inst Monograph 3: 47–52, 1985Google Scholar
  50. 50.
    Msirikale JS, Klein JL, Schroeder J Order SE: Radiation enhancement of radiolabelled antibody deposition in tumors. Intl J Radiat Oncol Biol Phys 13: 1839–1844, 1987Google Scholar
  51. 51.
    Neuwelt EA, Sprecht HD, Barnett RA, dahlborg SA, Miley A, Larson SM, Brown P, McKerman KF, Hellstron KE, Hellstrom I: Increased delivery of tumor specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to central nervous system. Neurosurgery 20: 885–895, 1987Google Scholar
  52. 52.
    Jain RK, Wei J: Dynamics of drug transport in solid tumors: Distributed parameter model. J Bioengineering 1: 313–330, 1977Google Scholar
  53. 53.
    Jain RK, Wei J, Gullino PM: Pharmacokinetics of methotrexate in solid tumors. J Pharmacokin Biopharm 7: 181–194, 1979Google Scholar
  54. 54.
    Stickney DR, Slater JB, Kirk GA, Ahlem C, Chang C, Frincke JM: Bifunctional antibody: ZCE/CHA-indium-111-BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody Immunoconjugates and Radiopharmaceuticals 2: 1–13, 1989Google Scholar
  55. 55.
    Senter PD, Saulnier MG, Scheiber GJ, Hirschberg DL, Brown JP, Hellstrom I, Hellstrom KE: Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 85: 4842–4846, 1988Google Scholar
  56. 56.
    Greiner JW, Guadagni F, Noguchi P, Prestka S, Colcher D, Fisher PB, Schlom J: Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesionsin vivo. Science 235: 895–898, 1987Google Scholar
  57. 57.
    Ward KA, Jain RK: Physiological response of tumors to hyperglycemia: Characterization, significance, and role in hyperthermia. International Journal of Hyperthermia 4: 223–250, 1988Google Scholar
  58. 58.
    Sitzman JV, Order SE, Klein JL, Leichner PK, Fishman EK, Smith GW: Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol 5: 1566–1573, 1987Google Scholar
  59. 59.
    Sasaki A, Jain RK, Maghazachi AA, Goldfarb RH, Herberman RB: Low deformability of LAK cells: A possible determinant ofin vivo distribution. Cancer Res 49: 3742–3746, 1989Google Scholar
  60. 60.
    Sasaki A, Melder RJ, Whiteside TL, Herberman RB, Jain RK: Preferential localization of human A-LAK cells in tumor microcirculation: A novel mechanism of adoptive immunotherapy (submitted)Google Scholar
  61. 61.
    Basse P, Wasserman K, Herberman RB, Goldfarb RH: Selective accumulation of adoptively transferred A-LAK cells in metastases of mouse B16 melanoma (submitted)Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Rakesh K. Jain
    • 1
  1. 1.Tumor Microcirculation Laboratory, Department of Chemical EngineeringCarnegie Mellon UniversityPittsburghUSA
  2. 2.Tumor Microcirculation Laboratory, Department of Chemical EngineeringCarnegie Mellon UniversityPittsburghUSA

Personalised recommendations